menu search

Intellia's (ntla) ind for gene-editing therapy gets fda clearance

Intellia (NTLA) gets FDA nod to begin a phase III study on its gene editing candidate, NTLA-2001 to treat tran...

October 19, 2023, 12:47 pm

Alnylam (alny) receives crl for the label expansion of onpattro

Alnylam's (ALNY) label expansion-seeking application for Onpattro, to treat transthyretin-mediated amyl...

October 10, 2023, 12:01 pm

Alnylam to scrap snda for patisiran after receiving fda complete response letter

Alnylam Pharmaceuticals Inc. ALNY, -1.00% said Monday it would no longer pursue its supplemental new drug application (sNDA) for patisiran as a treatm...

October 9, 2023, 7:43 am

Alnylam's (alny) onpattro snda gets fda advisory committee nod

Alnylam (ALNY) receives a positive opinion from the FDA's advisory committee regarding the label expansion of patisiran to treat the cardiomyopathy of...

September 14, 2023, 11:17 am

Bridgebio presents detailed positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) at european society of cardiology congress 2

– The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consisten...

August 27, 2023, 10:15 am

Bridgebio presents detailed positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) at european society of cardiology congress 2

– The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consisten...

August 27, 2023, 10:15 am

Bridgebio presents detailed positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) at european society of cardiology congress 2

– The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consisten...

August 27, 2023, 10:15 am

Bridgebio presents detailed positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) at european society of cardiology congress 2

– The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consisten...

August 27, 2023, 10:15 am

Bridgebio presents detailed positive results from phase 3 attribute-cm study of acoramidis for patients with transthyretin amyloid cardiomyopathy (attr-cm) at european society of cardiology congress 2

– The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consisten...

August 27, 2023, 10:15 am

Bridgebio pharma to present detailed results from the phase 3 attribute study in patients with transthyretin amyloidosis cardiomyopathy (attr-cm) at european society of cardiology (esc) congress 2023

PALO ALTO, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage...

August 24, 2023, 4:01 pm

Bridgebio pharma: positive attr-cm treatment data leads to other 2023 catalysts

Primary endpoint met in BridgeBio Pharma, Inc.'s phase 3 ATTRibute-CM study, which used acoramidis for the treatment of patients with ...

July 17, 2023, 6:42 pm

Bridgebio pharma stock soars on heart disease drug study results

BridgeBio Pharma Inc shares surged 69% to $30.78 in late-morning trading on Monday after the commercial-stage biopharmaceutical company announced that...

July 17, 2023, 11:33 am

: bridgebio’s stock rockets 66% on news of positive results from late-stage trial of attr-cm treatment

BridgeBio Pharma Inc.’s stock BBIO rocketed 66% in premarket trade Monday, after the company announced positive results in a late-stage trial of a t...

July 17, 2023, 11:32 am

Why is bridgebio (bbio) stock up 63% today?

BridgeBio Pharma (NASDAQ: BBIO ) stock is climbing higher on Monday as investors react to results from a Phase 3 clinical trial. These results come f...

July 17, 2023, 10:04 am

Bridgebio's stock rockets 66% on news of positive results from late-stage trial of attr-cm treatment

BridgeBio Pharma Inc.'s stock BBIO, +5.26% rocketed 66% in premarket trade Monday, after the company announced positive results in a late-stage trial ...

July 17, 2023, 7:32 am

Ionis (ions) posts encouraging data from amyloidosis drug study

Ionis (IONS) reports positive 85-week phase III study data, supporting the benefits of eplontersen as a treatment for hereditary ...

July 11, 2023, 11:03 am

Alnylam (alny) reports positive results from apollo-b study

Alnylam (ALNY) announces positive interim analysis results from the phase III APOLLO-B study of patisiran to treat ...

May 22, 2023, 1:35 pm

Bridgebio pharma reports first quarter 2023 financial results and business update

– Phase 3 ATTRibute-CM registrational trial of acoramidis for transthyretin amyloid cardiomyopathy (A...

May 4, 2023, 11:30 am

Ionis (ions) posts new upbeat data from amyloidosis drug study

Ionis (IONS) reports positive long-term phase III study data, supporting the benefits of eplontersen as a treatment for hereditary ...

March 27, 2023, 12:59 pm

Astrazeneca, ionis plan to seek fda approval for rare-disease therapy this year

U.S.-listed shares of AstraZeneca AZN, +2.98% were up 2.5% in trading on Tuesday after the company said an experimental therapy for hereditary ...

June 21, 2022, 11:19 am


Search within

Pages Search Results: